

ASX Announcement

Medibio Limited – 2 November 2018



Medibio Market Update

Sydney, Australia and Minneapolis, MN – 2 November 2018: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, today shares a market update to the recent quarterly update.

ISO 13485 Certification

This week the company completed the annual audit process for certification of the Company's Quality Management System. The audit was conducted by DQS Med, the Notified Body appointed to assess our compliance. There were no major or minor findings, providing further evidence of the stability of our quality system for design and manufacturing of medical devices. We are pleased with our team's preparation for the audit process and their ability to deliver against this competency.

Staff Reductions

As previously disclosed, the Company has implemented cost reduction measures that included eliminating certain staff positions in Minneapolis, MN. We thank those employees for their service and team contributions.

– END –

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (Wa) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

Further Information:

Website: www.medibio.com.au

Medibio Enquiries:

Kristi Hamilton
Senior Marketing Communications Manager
Medibio Limited
kristi.hamilton@medibio.com.au
T: +1 952 232 0934

Australian Media Enquiries:

Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231